MX2023002278A - Uso de un anticuerpo anti-pd-1 y un farmaco antineoplasico citotoxico en el tratamiento del cancer de pulmon no microcitico. - Google Patents

Uso de un anticuerpo anti-pd-1 y un farmaco antineoplasico citotoxico en el tratamiento del cancer de pulmon no microcitico.

Info

Publication number
MX2023002278A
MX2023002278A MX2023002278A MX2023002278A MX2023002278A MX 2023002278 A MX2023002278 A MX 2023002278A MX 2023002278 A MX2023002278 A MX 2023002278A MX 2023002278 A MX2023002278 A MX 2023002278A MX 2023002278 A MX2023002278 A MX 2023002278A
Authority
MX
Mexico
Prior art keywords
antibody
anticancer drug
lung cancer
small cell
cell lung
Prior art date
Application number
MX2023002278A
Other languages
English (en)
Inventor
Sheng Yao
Hui Feng
Original Assignee
Shanghai Junshi Biosciences Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Junshi Biosciences Co Ltd filed Critical Shanghai Junshi Biosciences Co Ltd
Publication of MX2023002278A publication Critical patent/MX2023002278A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/86—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a una combinación de un anticuerpo anti-PD-1 o un fragmento de unión a antígeno del anticuerpo anti-PD-1 y un fármaco antineoplásico citotóxico, y al uso de la combinación en la preparación de un medicamento para tratar el cáncer de pulmón no microcítico. Específicamente, la presente invención se refiere a una combinación de un anticuerpo anti-PD-1 o un fragmento de unión a antígeno del anticuerpo anti-PD-1, un fármaco antineoplásico antimetabolismo del folato y un fármaco antineoplásico de platino, y al uso de la combinación en la preparación de un medicamento para tratar el cáncer de pulmón no microcítico cuyo tratamiento con ITC del EGFR ha fracasado.
MX2023002278A 2020-08-28 2021-08-27 Uso de un anticuerpo anti-pd-1 y un farmaco antineoplasico citotoxico en el tratamiento del cancer de pulmon no microcitico. MX2023002278A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010883912 2020-08-28
CN202110925375 2021-08-12
PCT/CN2021/114982 WO2022042681A1 (en) 2020-08-28 2021-08-27 Use of an anti-pd-1 antibody and a cytotoxic anticancer drug in treatment of non-small cell lung cancer

Publications (1)

Publication Number Publication Date
MX2023002278A true MX2023002278A (es) 2023-03-10

Family

ID=80352732

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023002278A MX2023002278A (es) 2020-08-28 2021-08-27 Uso de un anticuerpo anti-pd-1 y un farmaco antineoplasico citotoxico en el tratamiento del cancer de pulmon no microcitico.

Country Status (10)

Country Link
US (1) US20230322930A1 (es)
EP (1) EP4204009A1 (es)
JP (1) JP2023539506A (es)
CN (1) CN115518162A (es)
AU (1) AU2021330883A1 (es)
BR (1) BR112023003154A2 (es)
CA (1) CA3191131A1 (es)
CL (1) CL2023000553A1 (es)
MX (1) MX2023002278A (es)
WO (1) WO2022042681A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113893342B (zh) * 2021-10-11 2024-01-30 蒋涛 一种含有抗pd-1抗体的药物组合物在制备治疗晚期非小细胞肺癌药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104250302B (zh) * 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
CN109806393B (zh) * 2017-11-17 2022-07-26 江苏恒瑞医药股份有限公司 抗pd-1抗体、培美曲塞和铂类药物联合治疗非小细胞肺癌的用途
AU2019288484A1 (en) * 2018-06-22 2021-01-21 Cugene Inc. Cytokine-based bioactivatable drugs and methods of uses thereof
CN110812485A (zh) * 2018-08-10 2020-02-21 江苏恒瑞医药股份有限公司 抗pd-1抗体联合化学疗法在制备治疗肿瘤的药物中的用途
CN110882385B (zh) * 2018-09-07 2021-07-09 上海君实生物医药科技股份有限公司 抗pd-1抗体在治疗肿瘤中的用途
WO2020092924A1 (en) * 2018-11-02 2020-05-07 Board Of Regents, The University Of Texas System Combination therapy for the treatment of egfr tyrosine kinase inhibitor resistant cancer

Also Published As

Publication number Publication date
CA3191131A1 (en) 2022-03-03
CN115518162A (zh) 2022-12-27
AU2021330883A1 (en) 2023-05-11
JP2023539506A (ja) 2023-09-14
EP4204009A1 (en) 2023-07-05
US20230322930A1 (en) 2023-10-12
AU2021330883A9 (en) 2023-07-13
CL2023000553A1 (es) 2023-08-25
WO2022042681A1 (en) 2022-03-03
BR112023003154A2 (pt) 2023-04-04

Similar Documents

Publication Publication Date Title
MX2020008882A (es) Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1.
Dillon et al. PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours
PH12019502484A1 (en) Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
PH12019502545A1 (en) Anti-cdh6 antibody and anti-cdh6 antibody-drug conjugate
Yang et al. NRG1-dependent activation of HER3 induces primary resistance to trastuzumab in HER2-overexpressing breast cancer cells
Lilenbaum et al. A Phase II Study of Induction Chemotherapy Followed by Thoracic Radiotherapy and Erlotinib in Poor-Risk Stage III Non–Small-Cell Lung Cancer: Results of CALGB 30605 (Alliance)/RTOG 0972 (NRG)
MX2018015393A (es) Anticuerpo lag-3, fragmento de union al antigeno del mismo y aplicacion farmaceutica del mismo.
PH12018500692A1 (en) Combination therapy for the treatment of cancer
MX2020008333A (es) Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales.
AU2010266004A8 (en) Method of treating cancer with Dll4 antagonist and chemotherapeutic agent
Saini et al. Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics
CR20230128A (es) Anticuerpo anti-nectina-4, conjugado que lo incluye y aplicación de los mismos
MX2020006171A (es) Terapia de combinacion con anticuerpos anti interleucina-8 (il-8) y anticuerpos anti receptor de muerte programada (pd-1) para tratar cancer.
BR112019023909A2 (pt) método para tratamento de um paciente com câncer de ovário, câncer peritoneal ou câncer de trompa de falópio.
MX2020010119A (es) Anticuerpo anti-cd27, fragmento de union a antigeno del mismo y uso medico del mismo.
MX2023002278A (es) Uso de un anticuerpo anti-pd-1 y un farmaco antineoplasico citotoxico en el tratamiento del cancer de pulmon no microcitico.
CR20220127A (es) Administración de dosis para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1
MX2023007178A (es) Complejo de anticuerpo anti-il-4r o fragmento de enlace a antigeno y uso medico del mismo.
MX2021010313A (es) Dosificacion para el tratamiento con anticuerpos anti-tigit y anti-cd20 o anti-cd38.
MX2021011529A (es) Chiauranib para el tratamiento de cáncer de pulmón microcítico.
MX2021003734A (es) Métodos de tratamiento del linfoma de linfocitos t periférico mediante terapia con conjugado fármaco-anticuerpo anti-cd30.
Burnett et al. A Phase 2a Open-Label Study to Investigate Safety and Tolerability (including the MTD), Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of MT-3724 in Combination with Gemcitabine and Oxaliplatin in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
MX2023006404A (es) Terapia combinada de anticuerpos y taxanos.
MX2022015769A (es) Tubulisinas y conjugados de proteina-tubulisina.
MX2021013248A (es) Regimenes de dosificacion para anticuerpos anti-vrs y composiciones que los incluyen.